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Brain inflammation is one of the hallmarks of Alzheimer disease (AD) and a current trend
is that inflammatory mediators, particularly cytokines and chemokines, may represent
valuable biomarkers for early screening and diagnosis of the disease. Various studies
have reported differences in serum level of cytokines, chemokines, and growth factors
in patients with mild cognitive impairment or AD. However, data were often inconsistent
and the exact function of inflammation in neurodegeneration is still a matter of debate.
In the present work, we measured the expression of 120 biomarkers (corresponding to
cytokines, chemokines, growth factors, and related signaling proteins) in the serum of
49 patients with the following diagnosis distribution: 15 controls, 14 AD, and 20 MCI.
In addition, we performed the same analysis in the cerebrospinal fluid (CSF) of 20 of
these patients (10 AD and 10 controls). Among the biomarkers tested, none showed
significant changes in the serum, but 13 were significantly modified in the CSF of AD
patients. Interestingly, all of these biomarkers were implicated in neurogenesis or neural
stem cells migration and differentiation. In the second part of the study, 10 of these
putative biomarkers (plus 4 additional) were quantified using quantitative multiplex ELISA
methods in the CSF and the serum of an enlarged cohort composed of 31 AD and
24 control patients. Our results confirm the potential diagnosis interest of previously
published blood biomarkers, and proposes new ones (such as IL-8 and TNFR-I). Further
studies will be needed to validate these biomarkers which could be used alone, combined,
or in association with the classical amyloid and tau biomarkers.
Keywords: Alzheimer disease, biomarkers, inflammation, cerebrospinal fluid, serum
Background
Alzheimer disease (AD) is the most common neurodegenerative disorder worldwide. It is
characterized by progressive memory loss and cognitive function deficit. Emerging evidences
suggest that inflammation plays a central role in AD, and that the pathogenesis of the disease is not
restricted to the neuronal compartment, but also involves immunologicalmechanisms.However, the
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exact function of inflammation in neurodegeneration is still mat-
ter of debate, and it probably has both beneficial and detrimental
sides (1).
The chronic inflammatory response occurring in AD patients
appears to be triggered by damaged neurons, amyloid beta
(Aβ) peptides, and neurofibrillary tangles (2), which are neu-
ropathogenic characteristics of the disease. Inflammation is
present from pre-clinical to terminal stages of the disease, as
reflected by activated microglia and reactive astrocytes that sur-
round plaques. Microglia activation is a complex phenomenon,
resulting in various phenotypes of the cells (secreting differ-
ent types of cytokines), indicative of their interaction with
the environment and allowing for either inflammatory or anti-
inflammatory responses. The reactive astrocytes that accumu-
late around the plaques participate in the clearance of Aβ
deposits and in cytokine secretion, thus enhancing the neuro-
inflammatory response initiated by microglia [for review, see
Ref. (3)].
Diagnosis of AD relies onmultidisciplinary approaches, requir-
ing in particular expensive imaging procedures and invasive col-
lection of cerebrospinal fluid (CSF) for biomarkers analysis (4):
Aβ (in particular Aβ42), tau, and phospho-tau (p-tau) proteins.
Anyway and because of the non-specificity of the symptoms char-
acterizing the disease, its diagnosis is often delayed at a time when
the injuries have progressed. The diagnosis of certitude is based
on the presence of two neuropathologic processes: neurofibril-
lary tangles and amyloid senile plaques composed of accumu-
lated tau proteins and Aβ peptides, respectively (5, 6). Despite
intensive investigation, there is no cure currently available but
only therapies that aim at slowing down the progression of neu-
ronal injuries (4). These drugs are mostly effective at the earliest
time course of the disease but are unfortunately administered
later, at a time when the diagnosis is defined and injuries have
progressed.
Because of the necessity of early diagnosis for optimal treatment
and adequate handling of the patients, a reliable signature of
specific biomarkers improving identification of pre-clinical AD
would be of great interest. If CSF remains the most direct mean to
study biochemical changes occurring in the brain, ideal biomark-
ers should be detectable and measurable in a fluid obtained
through less invasive technique, such as the blood. Various groups
have recently focused on the search of a plasma panel of AD
biomarkers, thus opening promising perspectives in terms of
diagnosis of the disease, including at prodromal stages (7–12).
However, results were often controversial, because in particular of
the heterogeneity of the population-based cohort used and/or the
limitation in the sensitivity of the methods used. Thus no blood-
based panel has been validated so far as an aid for the diagnosis of
AD (13, 14).
Because of the inflammatory component of AD, one can
hypothesize that pathological processes associated with this dis-
order would produce disease-specific molecular changes in the
CSF and the blood, as a consequence of the inflammatory mech-
anisms. Thus, cytokines, chemokines, and growth factors could
be expected to be modified, as these are the primary means of
communication between cells. They could therefore represent
valuable biomarkers for early screening and diagnosis of the dis-
ease. To test this hypothesis, we performed multiplex analysis of
CSF and serum human samples and simultaneously evaluated the
level of expression of 120 biomarkers (corresponding to cytokines,
chemokines, growth factors, and related signaling proteins) in
these fluids. We discuss our results in this paper, in light of
previously published results.
Materials and Methods
Sample Collection and Handling
Bloodwas collected by venous puncture (BD vacutainer collection
tube with clot activator, ref 368815), let it clot at room temperature
(RT) for at least 30min, centrifuged in the next 4 h at 1500 g at
RT for 10min. Serum supernatant was subsequently aliquoted
by 0.5mL in 1.5mL eppendorf microtube (Eppendorf Protein
LoBind, ref 0030 108.116) and stored at  80°C until analysis.
CSF samples were collected by lumbar puncture in polypropylene
tubes (Starstedt; 10mL, ref 62.610.201), according to standard
operating procedures (15), centrifuged at 1000 g at 4°C during
10min, and the supernatant aliquoted and stored as for serum
samples.
Patient Description and Samples
CSF and sera originated from a sample collection of patients
who gave their informed consent from Montpellier neurological
and Clinical Research Memory Centers (CMRR) for cognitive or
behavioral disorders (officially registered collectionDC-2008-417
of the certified NFS 96-900 biobank of the CHRU of Montpellier
BB-0033-00031). This study was ethically approved under the
number 12.128Ter by the “Comité consultatif sur le traitement de
l’information en matière de recherche” (CCTIRS).
Patients were selected based for AD on the clinical criteria
established in 1984 by the National Institute of Neurological
and Communicative Disorders and Stroke (NINCDS) and the
Alzheimer’s Disease and RelatedDisorders Association (ADRDA)
(16). MCI patients were selected following the Petersen MCI
diagnosis criteria (17) with a concern regarding a change in cog-
nition, impairment in one or more cognitive domains, preser-
vation of independence in functional abilities without dementia.
Mini-mental state examination (MMSE) values illustrating differ-
ences in cognition of the different clinical groups are provided in
Table 1.
For the microarrays approach, a total of 49 serum samples
were analyzed. Sera originated from control subjects (n= 15), AD
(n= 14), or MCI (n= 20) patients. Among these MCI patients,
10 showed biological characteristics of AD. Of note, the time
between the collection of the samples and their analysis was not
significantly different between groups (Table 1).We also analyzed
the CSF of 20 of these 49 patients (10 AD patients and 10 control
subjects).
In the second step, and as a validation study, we selected 31 AD
patients (9 of thembelonging also to the initial cohort) with a PLM
scale of 2 or 3 (18). We also selected 24 control patients (4 of them
belonging also to the initial cohort) with a PLM scale of 0 or 1 (18)
and the following diagnoses: amyotrophic lateral sclerosis (n= 1),
Parkinson (n= 2), progressive supranuclear palsy (n= 2), vas-
cular dementia (n= 3), normal pressure hydrocephalus (n= 2),
Lewy body dementia (n= 2), peripheral neuropathy (n= 1), and
subjective cognitive impairment (n= 11).
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TABLE 1 | Demographic and CSF biomarkers in the population.
Diagnosis p (t-test)
Control AD
N Mean SD N Mean SD
Age 24 66:63 13:30 31 70:84 8:71 0.162
Sex 24 0:67 0:48 31 0:52 0:51 0.17 (Fischer’s test)
IATI 24 1:91 0:72 31 0:95 0:65 <0.001
CSF Aβ42 (pg/mL) 24 1024:58 350:39 31 812:10 314:71 0.059
CSF p-Tau (pg/mL) 24 32:33 10:74 31 87:19 32:74 <0.0001
CSF Tau (pg/mL) 24 188:00 74:27 31 635:97 272:45 <0.0001
CSF protein (g/L) 22 0:49 0:15 29 0:51 0:20 0.397
Serum CRP (mg/L) 21 3:12 4:79 22 2:39 2:64 0.397
Mini-mental state examination (MMSE)/30 20 25:40 6:80 28 22:20 4:80 0.066
Demographic data, CSF biomarker levels (Aβ42, tau, and p-tau), IATI, CSF proteins, serum CRP (inflammation biomarker), and MMSE are shown for control and AD groups. Results
are presented as mean and SD. t-test and Fischer exact test were computed.
Protein-Arrays Analysis
The relative abundance of 120 known signaling proteins (Table S1
in Supplementary Material) was measured in the 69 biological
samples (49 sera and 20 CSF) using protein antibodies-based
arrays (RayBio® Human Cytokine Antibody Array G-Series 1000,
AAH-CYT-G1000-8). Antibodies used for detection of the 120
proteins are distributed on two slides (G6 and G7), each one
allowing the semi-quantitation of 60 of the signaling proteins
(see Table S1 in Supplementary Material for protein maps). Every
sample tested was thereafter and simultaneously hybridized on
two slides: G6 and G7.
One hundredmicroliters of native CSF or diluted serum (1:2.5)
of each patient was hybridized on the slides, according to the
provider’s recommendations. As an internal quality control, a
pool of five sera (originating from control patients) was prepared
in our laboratory and hybridized on every slide, thus ensur-
ing the control of the homogeneity of the results between the
arrays. Slides were scanned at 532 nm (GenePix 4200AL, Axon
instruments).
All the numeric data obtained following scan of the arrays were
normalized according to the manufacturer’s recommendations
[using the normalization file provided with the kit (AAH-CYT-
G1000-8, RayBio®)].
Quantitative Analysis Through ELISA and
Electrochemiluminescence Assays
Quantitative multiplex or simplex methods were performed
in both the CSF and serum of 55 patients (31 AD patients
and 24 control subjects), using either electrochemiluminescence
(MesoScaleDiscovery technology, MSD, Sector Imager 2400A) or
ELISA method. Quantification of FABP3, TIMP-1, MIP-1beta,
and RANTES was performed using simplex detection MSD kit,
while GRO-alpha, IL-8, MCP-1, MIP-3beta, and sTNFR-I were
simultaneously measured using MSD custom V-Plex detection
(MSDMULTI-SPOT® 7 Spot Special Order Human 5Plex). Quan-
tification of IGFBP-6, sIL-6R, IL-3, and MIP-1alpha was per-
formed through simplex ELISA, purchased from Clinisciences.
CSF samples were measured directly, without previous dilution.
Depending on the cytokinemeasured, serum sampleswere diluted
(1:2–1:50).
Statistical Analysis
For protein-arrays analysis, prediction analysis for microarrays
(PAM) was performed with normalized array measurements of
the 120 signaling proteins quantified in the training set (software
R 3.1). To minimize the risk of overfitting, the PAM approach
used as a training set 90% of the population, and as a validation
the remaining 10%. This cross-validation was repeated 10 times.
For exploitation of quantitative ELISA results, Student’s t-test and
area under ROC curves (AUC) analysis were performed using
medCalc® software ver 15.2.2. The logistic regressionwas achieved
with the same software with backward stepwise selection using a
significance level of 0.10. Classification trees were obtained using
a Microsoft Visual Studio routine (available upon request), which
computed the sensitivity and specificity of all possible pair com-
bination of biomarkers at the different cut-offs (corresponding to
the values of the biomarkers in the population).
Results
Semi-Quantitative Analysis of 120 Proteins
Through Protein-Arrays Approach
Forty-nine patients of clinically characterized diagnosis were
included for the protein-array analysis: the cohort was composed
of individuals with pre-symptomatic (MCI,mild cognitive impair-
ment, n= 20) or late-stage AD (n= 14) patients and from control
subjects (n= 15), Figure 1A. MMSE differed between the groups
and was, as expected, significantly correlated with Aβ42, Tau or
p-Tau (p< 0.001, “Spearman” rank correlation).
The serum of these 49 patients and the CSF of 20 of them
(10 controls and 10 AD) were hybridized simultaneously on G6
and G7 slides, in order to evaluate the relative abundance of
the 120 proteins detectable on the arrays (Figures 1A,B, left
panel). Before proceeding to the analysis of the slides and to
ensure for their homogeneity, an internal quality control (CQI)
was hybridized on every array, in the very same conditions than
biological samples included in that study. This CQI corresponds
to a pool of sera (originated from control subjects) prepared in
our laboratory and was used to compare and homogenize the
slides, so that the fluorescence detected could be attributed to
specific variation of expression of the proteins in a sample, rather
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diagnosis
Control (A)
Alzheimer disease. 
AD (B)
MCI
non AD profile (C) AD profile (D)
N 15 14 10 10
men 7 10 7 6
women 8 4 3 4
Biological sample analysed serum + CSF serum + CSF serum serum
Time between collection of  sample and analysis (months) 18.4 ± 7.1 20.8 ± 3.7 20.3 ± 4.5 18.2 ± 7.3
Mini-Mental State Examination (MMSE) /30 22.9 ± 5.8 21.8 ± 5.8 28.4 ± 1.1 24.7 ± 4.5 
PROTEIN-ARRAY ANALYSIS
SERUM
A-Control (n=15) 
B-AD (n=14)
C-MCI. non AD proﬁle (n=10)
D-MCI. AD proﬁle (n=10)
CSF
A-Control (n=10) 
B-AD (n=10)
PAM analysis
=> 13 predictors iden!ﬁed (in the CSF)
SERUM data pool for analysis
Groups A-C. n=25 
Groups B-D.  n=24
CSF
A-Control (n=10) 
B-AD (n=10)
CQI
Pool of 5 serum
Control for array
homogeneity (CQI)
=> Extrac!on of non 
homogeneous slides  for analysis
Student t-test analysis
=> no predictor iden!ﬁed
1
2
A
B
FIGURE 1 | Cohort patients and study outline. (A) A total of 49 patients
were included in the preliminary study for protein-arrays analysis: 15 control
subjects (A), 14 AD late-stage patients (B) and 20 MCI (mild cognitive
impairment): 10 MCI with non-AD profile (C) and 10 MCI presenting AD profile
(D). Serum was analyzed for every patient included; CSF was analyzed for 20 of
them (10 patients from groups A and B). Time between collection of samples
(serum and CSF) and their analysis is indicated (in months): results are
meanSD. Mini-mental state examination (MMSE) is indicated (MMSE/30) as
meanSD. (B) Sera, CSF, and our internal quality control (CQI, corresponding
to a pool of five control sera) were hybridized on the protein arrays.
Homogeneity of the slides was controlled thanks to the CQI: non-homogeneous
slide identified was extracted before proceeding to the analysis of the arrays.
Normalized array data of 120 serum signaling proteins were analyzed in the
training set with statistical Student’s t-test to discover differences in protein
abundance between samples (strategy 1). As no predictor could be identified,
serum data were pooled for groups A–C and B–D (strategy 2). To discover
predictors for classification, the training set was analyzed through prediction
analysis for microarrays (PAM) approach.
than a slide effect (Figure 1B, left and central panels and Data
S1 in Supplementary Material). Our data show that CQI inter-
slide are homogenous between G7 slides, which validated the
subsequent analysis of numeric data obtained for the proteins
studied on these arrays (Data S1 in Supplementary Material, left
graph). On the other hand, analysis of CQI on G6 slides showed
that one of these arrays gave non-homogenous results (Data S1,
right graph, gray-highlighted results); the corresponding slide was
thereafter extracted before proceeding to the subsequent analysis
(Figure 1B, central panel).
Following this preliminary control of the slides, normalized
data generated from the 49 sera and 20 CSF hybridized were
analyzed through semi-quantitative protein-arrays approach: the
relative abundance of 120 proteins of known function (cytokines,
chemokines, and other signaling proteins) was simultaneously
evaluated (Figure 1B, right panel).
The numeric and normalized data obtained from the protein
arrays were first of all analyzed through Student’s t-test, in order
to identify a set of putative biomarkers in the serum that could
participate to the discrimination of control, MCI, and late-stage
AD patients (Figure 1B, right and up panel); however, this statis-
tical analysis did not provide exploitable results, as no biomarker
appeared to be significantly and specifically associated to one
group more than another one (results not shown). Furthermore,
we decided to pool together the data obtainedwith the serumof all
the AD patients (MCI with AD profile and late-stage) and control
patients (control and MCI no AD profile) and to focus on the
discrimination between control and AD patients (Figure 1B, right
panel strategy 2). Prediction analysis for microarrays (PAM) was
thereafter performedwith the normalized arraymeasurements. In
the serum, we were still unable to identify proteins significantly
modified between the two groups. On the other hand, the same
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analysis in the CSF led to the discovery of a repeatedly optimal
set of 13 predictors giving the lowest possible classification error
between control and AD groups (Figures 2A,B). Results showed
that all of them were decreased in AD group (negative d-score,
Figure 2B).
Quantitative Analysis of Putative Biomarkers in
the CSF and the Serum
Among the 13 putative proteins of interest identified in the
CSF, 10 of them (plus 4 additional selected following literature)
were subsequently analyzed through quantitative method in the
CSF and the serum of AD and control patients. This quan-
tification was performed on an enlarged cohort, composed of
55 individuals (31 AD patients and 24 control subjects), char-
acterized clinically and biologically for CSF biomarkers: Aβ42,
tau, and p-tau (Table 1; Figure 3). According to their clinical
diagnosis, AD patients showed a decrease of CSF Aβ1–42, together
protein idenﬁcaon      control-score             AD-score
TIMP-1 0.1401 -0.1401
IL-11 0.137 -0.137 
sTNF-RI 0.1187 -0.1187
MIP-3beta 0.1036 -0.1036
Thrombopoien 0.0589 -0.0589
sIL-6R 0.0529 -0.0529
TGF-beta1 0.052 -0.052 
MCP-1 0.0303 -0.0303
GRO 0.0303 -0.0303
IL.3 0.0165 -0.0165
IL.8 0.0125 -0.0125
IGFBP6 0.0113 -0.0113
GRO-alpha 0.0029 -0.0029
optimal number of predictorsA
B
FIGURE 2 | Predictors discovery. (A) Predictor discovery by prediction
analysis for microarrays (PAM) was performed with normalized array
measurements of 120 signaling proteins in the training set. Internal
cross-validation (redline) decreasing the centroid threshold (lower x-axis)
resulted in an increase in the number of markers (inserted upper x-axis) that
were used for classification and calculation of the classification error (y-axis).
This led to the discovery of an optimal set of 13 predictors with lowest
possible classification error. (B) The 13 predictors identified through PAM
analysis are presented. Proteins are arranged in columns, with d-score
corresponding in each group. Control group corresponded to control subjects
and MCI non-AD patients (groups A–C defined for protein-arrays analysis); AD
group corresponded to AD late-stage patients and MCI presenting AD profile
(groups B–D defined for protein-arrays analysis). Positive d-score is indicative
of increased expression and negative d-score reflects decrease in the
expression of the proteins analyzed.
with an increase of CSF tau and p-tau (p< 0.0001). The ratio
IATI [Aβ1–42/(240+ 1.18 tau)] was calculated for these patients
and allowed for diagnostic discrimination of the two groups
(p< 0.001, Figure 3D). Groups were homogeneous in terms of
age, sex repartition, CRP, and CSF protein, and MMSE was
decreased in AD group (Table 1).
We tested for normal distribution of the data concerning the
14 proteins measured and thereafter proceeded for t-student sta-
tistical test to evaluate significant difference between AD and
control groups (Table 2). Results showed that in the CSF, among
the 14 tested proteins, 3 biomarkers were significantly different
between the two groups (Table 2, bolded and gray-highlighted
results): sIL-6R, TIMP-1, and sTNFR-I. These three proteins were
increased in the CSF of AD patients, compared to control sub-
jects (Figures 4A–C). Furthermore, three of the 14 biomarkers
quantifiedwere undetectable in theCSF of patients (FABP3,GRO-
gamma, and TGF-beta1). On the other side, all of the 14 biomark-
ers tested were detectable in the serum but none of them were
detected at a level significantly different between AD and control
patients (Table 2; Figures 4D–F).
ROC Curves, Regression Analysis and Decision
Trees of the Biomarkers in the Serum and the
CSF
We compared the area under the ROC curves (AUC) of all
the analytes measured in the serum and the CSF of the 55
patients (Table 3). CSF tau and p-tau appeared to be the
most efficient analytes to discriminate AD patients and control
subjects (AUC values= 0.942 and 0.946, respectively). Among
the analytes tested, seven presented an AUC 0.655 (Table 3,
bolded and highlighted results). To combine these CSF biomark-
ers, we tested a logistic regression model which retained three
biomarkers with the following equation: sIL6R 0.0034615+
TIMP1 0.000024458+TNFRI 0.001016  9.2101 (pg/mL).
As illustrated in Figure 5A, this resulted in an important improve-
ment of the AUC reaching 0.858 (corresponding at its best to a
sensitivity of 74.2% and a specificity of 91.7%). The relevance of
these biomarkers for AD was also supported by the fact that a
significant “Spearman” rank correlation was observed between
MMSE and CSF TIMP-1 (p= 0.03950) and between tau or p-tau
and CSF sIL6R (p< 0.001). The low differences in expression of
the biomarkers in the blood prevented their integration in the
logistic regression model.
We also tested a simple classification tree model based on
only two analytes (nodes) to minimize the risk of overfitting
(Figures 5B,C). For the CSF biomarkers, this resulted in a classi-
fication involving IGFBP6 andMIP-3 beta, reaching on their own
a sensitivity of 81% and a specificity of 92% (Figure 5B). Interest-
ingly, the logistic regression and the classification tree resulted in
a different biomarker selection and the patients selected with the
twomodelswere also different. Additional studies on larger cohort
will be needed to reconcile and eventually combine these results.
Applying the same approach for serum biomarkers, it resulted in
a classification involving IL-8 and TNFR-1, reaching a sensitivity
of 77% and a specificity of 75% (Figure 5C).
Of note, the control misclassified patients of the classification
trees (Figures 5B,C) corresponded to various diagnoses (Lewy
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FIGURE 3 | Clinical biochemical characterization of patients. The 55
patients (AD, n= 31 and control subjects, n= 24) of the enlarged cohort used
for the second part of the study were characterized clinically and quantified for
CSF biomarkers: Aβ42, tau, and p-tau, using Fujirebio ELISA quantification kits
(A–C). IATI ratio [Aβ42/(240+ 1,18tau)] (D) was calculated for every subject of
the cohort. Outliers are indicated with black circle. Outliers are defined as a
value that is smaller than the lower quartile minus three times the interquartile
range, or larger than the upper quartile plus three times the interquartile range.
body dementia, vascular dementia, and subjective cognitive
impairment). Based on the available clinical and biological data,
it was not apparent why these patients were misclassified.
Discussion
The 2011 revision of criteria for AD clinical diagnosis includes
CSF biomarkers analysis: quantification of Aβ42 peptides, tau,
and p-tau proteins; however and despite its utility, its use in
routine clinical practice and for the follow-up of patient is limited
because in particular of the invasive character of lumbar puncture.
The link between neuro-inflammation and AD has opened
attractive perspectives for the early diagnosis and handling of
patients. Indeed, the possibility to identify a blood-based panel
of biomarkers to detect AD patients could allow for a system-
atic and early diagnosis of them, at the time of the first signs
indicative of cognitive impairment, therefore optimizing their care
and treatment. In addition, the perspective of feasibility of an early
biochemical diagnosis of patients through minimally invasive
technique (such as venous puncture) is quite seducing.
Various studies described such a signature in the blood: among
them, Ray et al. identified 18 blood biomarkers, some of which
were subsequently confirmed by ADNI (8, 19). The present work
aimed at investigating the molecular mechanisms involved in
inflammatory processes occurring in AD, intending to identify or
confirm a profile of biomarkers characteristic of AD. To this end,
the modification of various signaling proteins (chemokines and
cytokines) in theCSF and the serumofADpatientswere evaluated
using multiplex strategies.
The protein-arrays approach used in the first place is very
attractive because it offers the opportunity to evaluate, in a sin-
gle test and through a reduced volume of biological sample,
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TABLE 2 | CSF and serum quantification of predictors identified.
Diagnosis p (t-test)
Control AD
N Mean SD N Mean SD
CSF FABP-3 (pg/mL) 24 ND ND 31 ND ND –
GRO-alpha (pg/mL) 24 22.79 12.28 31 29.97 18.63 0.101
GRO-gamma (pg/mL) 24 ND ND 27 ND ND –
IGFBP6 (pg/mL) 24 76,4473.50 680,240.30 31 65,6967.45 317,572.10 0.440
IL-3 (pg/mL) 24 71.08 55.42 31 81.94 141.47 0.721
IL-8 (pg/mL) 24 2476.46 2164.15 31 3398.90 3307.04 0.242
MCP-1 (pg/mL) 24 484.54 110.74 31 524.87 221.39 0.420
MIP-1beta (pg/mL) 24 11.38 7.89 31 11.58 3.09 0.957
MIP-3beta (pg/mL) 24 193.33 137.71 31 249.97 110.29 0.096
RANTES (pg/mL) 24 4.25 8.36 31 9.81 20.49 0.210
sIL6-R (pg/mL) 24 1125.71 304.31 31 1455.42 384.44 0.001
TGF-beta1 (pg/mL) 24 ND ND 31 ND ND –
TIMP-1 (pg/mL) 24 94,953.75 23,724.34 31 117,507.10 31,685.66 0.005
sTNFR-I (pg/mL) 24 2058.88 700.90 31 2601.94 693.10 0.006
Serum FABP-3 (pg/mL) 24 7.13 2.47 31 6.36 2.44 0.247
GRO-alpha (pg/mL) 23 106.50 64.10 31 111.10 56.08 0.777
GRO-gamma (pg/mL) 24 98.91 231.92 27 128.44 258.91 0.676
IGFBP6 (pg/mL) 24 887,849.71 565,626.11 31 717,297.23 325,456.73 0.306
IL-3 (pg/mL) 24 2353.25 7191.47 31 1242.19 1409.37 0.372
IL-8 (pg/mL) 24 21.42 17.54 31 17.36 16.77 0.392
MCP-1 (pg/mL) 24 319.21 100.39 31 319.13 99.70 0.993
MIP-1beta (pg/mL) 24 28.67 13.78 31 28.45 16.95 0.957
MIP-3beta (pg/mL) 24 230.71 452.88 31 154.94 188.86 0.403
RANTES (pg/mL) 24 189.58 93.68 31 216.16 117.38 0.368
sIL6-R (pg/mL) 24 88,788.79 30,096.89 31 79,709.42 26,040.66 0.236
TGF-beta1 (pg/mL) 24 1.13 0.34 31 1.26 0.44 0.677
TIMP-1 (pg/mL) 24 65,6950 248,683.10 31 660,009.68 342,382.44 0.971
sTNFR-I (pg/mL) 24 5139.29 1880.56 31 4424.97 1242.77 0.096
Ten predictors previously identified following PAM analysis and four supplemental ones (FABP3, GRO gamma, RANTES, and MIP-1beta) were quantified in the CSF and the serum of
AD (n=31) and control (n=24) patients using quantitative ELISA and MSD approaches. Results are presented as mean and SD. The three bolded and gray-highlighted biomarkers
present significant difference in the CSF between control and AD groups (Student’s t-test). None of the proteins tested in the serum show significant difference between the two groups.
ND corresponds to proteins undetectable in the CSF.
the simultaneous level of expression of numerous proteins. In
the present study, the large screening of 120 signaling pro-
teins in serum and CSF of AD patients seemed very promising
but appeared unfortunately quite disappointing in the serum.
Indeed, no putative biomarker could be identified through this
approach. One cannot exclude the possibility that the protein-
arrays approach might lack sensitivity and reproducibility to
detect small and discrete differences in the level of expression of
the proteins tested between the groups of our cohort. Anyway such
observation remains quite intriguing because other studies, using
similar approaches, described a blood-based panel of biomarkers
discriminating control subjects and AD patients (8). However,
a strict comparison of these works remains challenging because
of the heterogeneity and the different size of the cohorts used,
and also because of the nature of the samples used (serum versus
plasma). On the other hand, the technique provided interesting
results in the CSF, as 13 putative biomarkers potentially dis-
criminating control subjects and AD patients could be identified.
Although such method is very useful as a first-step and large
screening of candidates, it remains semi-quantitative and poorly
sensitive. Thus, the putative biomarkers identified in the CSF had
to be subsequently tested for confirmation through quantitative
and sensitive methods.
Among the 13 predictors identified, 10 were analyzed through
such quantitative approaches, according to the availability of
the existent kits: GRO-alpha, IGFBP6, IL-3, IL-8, MCP-1, MIP-
3beta, sIL-6R, TGF-beta1, TIMP-1, and sTNF-RI. Because of
their potential implication in inflammatory processes and AD,
we also evaluated the abundance of four supplemental proteins
present in our panels: GRO-gamma, RANTES, MIP-1beta, and
FABP3, which were also described in the literature as putative
AD biomarkers. These 14 proteins were quantified in both the
CSF and the serum of an enlarged cohort of 55 subjects (AD
patients and control individuals). Among these biomarkers, three
presented significant increase in the CSF: sIL-6R, TIMP-1, and
sTNFR-I, and could be combined in a logistic regression model.
Interestingly, sIL-6R and sTNF-RI presented opposite way of
variation in the serum, although not being significant in this fluid.
Microglia and astrocytes are the major sources of cytokines
production in AD. Thus, Aβ42 accumulation has been suggested
to be a strong inducer of the neuro-inflammatory response in AD,
exposure of microglia to Aβ42 deposits increasing production of
IL-6 and M-CSF (20). M-CSF was also described to be increased
in the plasma and the CNS of patients at the dementia stage of
AD compared to control or MCI age-matched patients (20, 21).
Controversial results were obtained by Ray et al., describing a
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FIGURE 4 | Predictors quantification in the CSF and the serum. sIL-6R,
TIMP-1, and sTNFR-I were quantified in the CSF (A–C) and in the serum (D–F)
of 55 patients (AD, n=31 and control subjects, n= 24). Outliers are indicated
with black circle. Outliers are defined as a value that is smaller than the lower
quartile minus three times the interquartile range, or larger than the upper
quartile plus three times the interquartile range.
decrease of M-CSF in the plasma of AD patients (8). In our study,
this cytokine presented a very low basal level and did not show
any significant modification of level neither in the CSF or serum
of our patients (protein-array results). In addition, IL-6 was barely
detectable in the CSF and serum of our patients but as noticed
above, its receptor (sIL-6R) was significantly increased in the CSF
and showed a tendency to decrease in the serum of AD patients
although not being significant. A CSF cytokine profile charac-
terized by an increase of TNF-alpha associated with a decrease
of TGF-beta could be a marker of the conversion of MCI to AD
(22). In addition, TNF-alpha was reported to be decreased in the
plasma of AD patients versus control (8). In our study anyway,
we did not observe significant change in the CSF or the serum of
TNF-alpha and TGF-beta level among the patients. Interestingly,
the receptor of TNF-alpha (sTNFR-I) was significantly increased
in the CSF of AD patients compared to control subjects and
showed a tendency to decrease in the serum of AD patients. Of
note, He et al. recently demonstrated that deletion of TNF-RI
can inhibit Aβ generation and prevents cognitive deficits in AD
mice (23), through the reduction of expression and activity of
BACE1 mediated by NF-κB signaling. Thus, chronic overexpres-
sion of neuronal TNF-alpha has been described to enhance local
inflammatory responses in transgenic ADmice (24). However, the
pro-inflammatory cytokine TNF-alpha is also reported to present
neuroprotective effects in the brain (25). In addition and very
interestingly, analysis of AUC of ROC curves in our study shows
that association of sTNF-RI was among the best biomarkers and
that its combination with TIMP-1 and sILR-6 provides the most
powerful combination for AD diagnosis. Such observation will
have to be confirmed in another study through an enlarged cohort.
On the other side, IL-3 is described in the literature to be
reduced in the plasma of AD patients, which was also observed
in our cohort (although not being significant). In addition, IL-
1beta is known to be secreted by activated microglia cells follow-
ing Aβ42 stimulation in vitro (26). Thus this pro-inflammatory
cytokine can be detected in microglial cells surrounding Aβ
deposits and in the CSF of AD patients (26). Anyway, only very
low level of this cytokine was detectable in the CSF and serum of
our patients and no difference in its concentration could be noted
among the patients. IGFBP6 is also described to be increased in
the plasma of AD patients (8) but we did not detect significant
changes of its level in our study. Interestingly, this molecule was
retained in the classification treemodel, whichwould need further
validation in a larger cohort.
Chemio-attractive chemokines are known to participate in the
inflammatory process of AD, through regulation of microglial
cells migration at the site of inflammation (27). In particular,
CCL4 (MIP-1beta) has been described in reactive astrocytes sur-
rounding Aβ deposits (28) and CXCL8 (IL-8), CCL2 (MCP-1),
and CCL3 (MIP-1alpha) are increased following Aβ42 exposition
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TABLE 3 | Values of area under the ROC curves.
Variable AUC SE 95% CI
CSF IATI 0.788 0.0739 0.636–0.898
Abeta 1–42 0.69 0.0789 0.550–0.807
GRO-alpha 0.604 0.0794 0.463–0.733
IGFBP6 0.511 0.0867 0.372–0.648
IL-3 0.566 0.0748 0.425–0.699
IL-8 0.614 0.0792 0.473–0.742
MCP-1 0.503 0.0791 0.365–0.641
MIP-1beta 0.655 0.0776 0.514–0.778
MIP-3beta 0.727 0.0787 0.590–0.839
p-Tau 0.946 0.0315 0.849–0.989
RANTES 0.618 0.0748 0.477–0.745
sIL6-R 0.755 0.0659 0.620–0.861
Tau 0.942 0.034 0.843–0.987
TIMP-1 0.692 0.0756 0.544–0.816
sTNFR-I 0.699 0.0771 0.551–0.821
CSF protein 0.514 0.0854 0.367–0.660
Serum CRP 0.512 0.0924 0.355–0.667
Fabp-3 0.646 0.0817 0.497–0.778
GRO-alpha 0.57 0.0873 0.421–0.710
GRO-gamma 0.579 0.076 0.430–0.719
IGFBP6 0.586 0.0801 0.445–0.717
IL-3 0.549 0.0797 0.409–0.684
IL-8 0.599 0.081 0.459–0.729
MCP-1 0.501 0.0806 0.363–0.639
MIP-1beta 0.548 0.0821 0.408–0.683
MIP-3beta 0.622 0.0761 0.481–0.750
RANTES 0.556 0.079 0.416–0.690
sIL6-R 0.595 0.0789 0.455–0.726
TGF-beta1 0.567 0.0528 0.426–0.700
TIMP-1 0.52 0.0795 0.381–0.657
sTNFR-I 0.625 0.0838 0.484–0.752
Area under the ROC curve (AUC) for all the biochemical analytes quantified in the 55
patients (AD, n=31 and control subjects, n=24) of the study was evaluated. The seven
biomarkers bolded and gray-highlighted analytes present AUC 0.650.
of astrocytes (29, 30). IL-8 has also previously been described to
be increased in the plasma of AD patient (8). In our study, we
detected increase of IL-8 and MCP-1 in the CSF of AD patients
and no significant modification of MIP-1alpha or beta, neither in
the CSF nor the serum.
On the other side, CCL5 (RANTES) was described to be down-
regulated in the plasma of AD patients (8) and we noted no
significant variation of this chemokine between the two groups
of our study. GRO-alpha has also been reported to be a CSF
biomarker of interest for AD diagnosis (31) but its level remained
unchanged between our two groups. GRO-gamma (CXCL3) was
undetectable in the CSF of our patients and remained unchanged
in the serum among the patients.
In addition, matrix metalloproteinases (MMP) are believed to
be involved in the pathologic processes of AD. TIMP-1 is the tissue
inhibitor of MMP-9 and has been described to be increased in the
CSF of AD and MCI patients (32). In our study, TIMP-1 was also
significantly increased in theCSFofADpatients. Its level appeared
stable in the serum of all populations of our cohort.
Finally, obesity, defined as a disorder in which excess fat accu-
mulates in the body, also induces chronic inflammatory processes.
Indeed, obesity has been associated with higher risk to develop
AD (33). FABP3 is a member of the fatty acid binding proteins
and has recently been described to be down-regulated in the brain
of AD patients (34). However, FABP3 was not detectable in the
CSF and presented no significant variation in the serum of our
patients.
Identification of a molecular signature for AD diagnosis is very
promising in terms of handling of patients and early diagnosis
of AD, but remains quite challenging. Indeed, numerous studies
have described panels of biomarkers of potential interest but at
the time of their confirmation, results appeared to be largely
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FIGURE 5 | Area under ROC curve (AUC) of Tau, p-Tau, and
sTNFR-I. ROC curves (A) of the three most efficient biomarkers for AD
diagnosis sIL-6R, TIMP-1, and sTNFR-I were plotted along with their
combination (logistic regression, see text). The classification tree for CSF
biomarkers (B) defined as AD samples those with IGFBP6
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(C), the criteria selected for AD diagnosis was: IL8 <23pg/mL and
TNFR-I <5260pg/mL.
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controversial [for review, see Ref. (3)]. Our study led us to identify
three differential biomarkers in the CSF of AD patients (sIL-
6R, TIMP-1, and sTNFR-I), which could be efficiently combined.
They were, however, not differential in the serum. On the other
hand, using classification trees, we could obtain notable results in
both CSF and serum, involving, respectively, IGFBP6 and MIP-3
beta or IL-8, and TNFR-I. Upon confirmation, these results could
represent interesting new means for the diagnostic of AD. These
biomarkers, associated with the biochemical diagnostic tools cur-
rently used forADdiagnosis (such asCSF biomarkersAβ, tau, and
p-tau), could be of particular interest for early diagnosis of AD or
for patients presenting ambiguous profiles.
In conclusion, this study confirms the potential diagnosis inter-
est of previously published blood biomarkers, and proposes new
ones (such as IL-8 and TNFR-I). Further studies will be needed to
validate these biomarkers which could be used alone, combined,
or in association with the classical CSF biomarkers.
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Table S1 | Antibody array map of G6 and G7 slides. Each array allowed for the
detection and semi-quantitation of 60 human cytokines. POS and NEG correspond
to positive and negative control, respectively, and are used for normalization of
fluorescence detected from the slides.
Data S1 | CQI homogeneity between arrays. CQI was hybridized on each
array (G6 and G7) in the very same conditions than the biological samples studied.
Non-homogenous slide (G6, gray-highlighted) was extracted before analysis of the
normalized data generated.
References
1. Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer’s dis-
ease: a source of heterogeneity and target for personalized therapy.Neuroscience
(2014) 302:103–11. doi:10.1016/j.neuroscience.2014.09.061
2. Akiyama H. Inflammation and Alzheimer’s disease. Neurobiol Aging (2000)
21(3):383–421. doi:10.1016/S0197-4580(00)00124-X
3. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein
DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol (2015)
14(4):388–405. doi:10.1016/S1474-4422(15)70016-5
4. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and
plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6(3):131–44.
doi:10.1038/nrneurol.2010.4
5. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther
K. Amyloid plaque core protein inAlzheimer disease andDown syndrome. Proc
Natl Acad Sci U S A (1985) 82(12):4245–9. doi:10.1073/pnas.82.12.4245
6. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder
LI. Abnormal phosphorylation of the microtubule-associated protein tau
(tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986)
83(13):4913–7. doi:10.1073/pnas.83.13.4913
7. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, et al. Blood-
based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol
(2012) 69(10):1318–25. doi:10.1001/archneurol.2012.1282
8. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al.
Classification and prediction of clinical Alzheimer’s diagnosis based on plasma
signaling proteins. Nat Med (2007) 13(11):1359–62. doi:10.1038/nm1653
9. O’Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M,
et al. A blood-based screening tool for Alzheimer’s disease that spans serum
and plasma: findings from TARC and ADNI. PLoS One (2011) 6(12):e28092.
doi:10.1371/journal.pone.0028092
10. LlanoDA, Laforet G, DevanarayanV. Derivation of a newADAS-cog composite
using tree-based multivariate analysis: prediction of conversion from mild
cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord (2011)
25(1):73–84. doi:10.1097/WAD.0b013e3181f5b8d8
11. Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R,
et al. Plasma proteins predict conversion to dementia from prodromal disease.
Alzheimers Dement (2014) 10(6):799e–807e. doi:10.1016/j.jalz.2014.05.1749
12. HuWT,HoltzmanDM, FaganAM, Shaw LM, Perrin R, Arnold SE, et al. Plasma
multianalyte profiling in mild cognitive impairment and Alzheimer disease.
Neurology (2012) 79(9):897–905. doi:10.1212/WNL.0b013e318266fa70
13. Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer’s dis-
ease: challenging but feasible. Biomark Med (2010) 4(1):65–79. doi:10.2217/
bmm.09.84
14. Galasko D, Golde TE. Biomarkers for Alzheimer’s disease in plasma, serum and
blood – conceptual and practical problems.Alzheimers Res Ther (2013) 5(2):10.
doi:10.1186/alzrt164
15. del CampoM, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simon-
sen AH, et al. Recommendations to standardize preanalytical confounding
factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers:
an update. Biomark Med (2012) 6(4):419–30. doi:10.2217/bmm.12.46
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM.
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDAWork
Group under the auspices of Department of Health and Human Services Task
Force on Alzheimer’s Disease. Neurology (1984) 34(7):939–44. doi:10.1212/
WNL.34.7.939
17. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E.
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol
(1999) 56(3):303–8. doi:10.1001/archneur.56.3.303
18. Lehmann S, Dumurgier J, Schraen S, Wallon D, Blanc F, Magnin E, et al. A
diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker
profiles. Alzheimers Res Ther (2014) 6(3):38. doi:10.1186/alzrt267
19. Johnstone D, Milward EA, Berretta R, Moscato P, Alzheimer’s Disease Neu-
roimaging Initiative. Multivariate protein signatures of pre-clinical Alzheimer’s
disease in the Alzheimer’s disease neuroimaging initiative (ADNI) plasma
proteome dataset. PLoS One (2012) 7(4):e34341. doi:10.1371/journal.pone.
0034341
20. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM Jr, et al. Inflam-
matory repertoire of Alzheimer’s disease and nondemented elderly microglia
in vitro. Glia (2001) 35(1):72–9. doi:10.1002/glia.1072
21. Laske C, Stransky E, Hoffmann N, Maetzler W, Straten G, Eschweiler GW, et al.
Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients
with mild cognitive impairment and Alzheimer’s disease. Curr Alzheimer Res
(2010) 7(5):409–14. doi:10.2174/156720510791383813
22. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation
precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry
(2003) 74(9):1200–5. doi:10.1136/jnnp.74.9.1200
23. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, et al. Deletion
of tumor necrosis factor death receptor inhibits amyloid beta generation and
prevents learning and memory deficits in Alzheimer’s mice. J Cell Biol (2007)
178(5):829–41. doi:10.1083/jcb.200705042
24. JanelsinsMC,MastrangeloMA, Park KM, Sudol KL, NarrowWC,Oddo S, et al.
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the
local inflammatory environment ultimately leading to neuronal death in 3xTg-
AD mice. Am J Pathol (2008) 173(6):1768–82. doi:10.2353/ajpath.2008.080528
25. Figiel I. Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in
the brain. Acta Neurobiol Exp (Wars) (2008) 68(4):526–34.
26. Akama KT, Van Eldik LJ. Beta-amyloid stimulation of inducible nitric-oxide
synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha
(TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor-
and NFkappaB-inducing kinase-dependent signaling mechanism. J Biol Chem
(2000) 275(11):7918–24.
27. Savarin-Vuaillat C, Ransohoff RM. Chemokines and chemokine receptors
in neurological disease: raise, retain, or reduce? Neurotherapeutics (2007)
4(4):590–601. doi:10.1016/j.nurt.2007.07.004
28. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study
of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal
Frontiers in Neurology | www.frontiersin.org August 2015 | Volume 6 | Article 18110
Delaby et al. Inflammation in Alzheimer’s disease
and Alzheimer’s disease brains. Am J Pathol (1998) 153(1):31–7. doi:10.1016/
S0002-9440(10)65542-3
29. Smits HA, Rijsmus A, van Loon JH, Wat JW, Verhoef J, Boven LA, et al.
Amyloid-beta-induced chemokine production in primary humanmacrophages
and astrocytes. J Neuroimmunol (2002) 127(1–2):160–8. doi:10.1016/S0165-
5728(02)00112-1
30. StuartMJ, Baune BT. Chemokines and chemokine receptors inmood disorders,
schizophrenia, and cognitive impairment: a systematic review of biomarker
studies.Neurosci Biobehav Rev (2014) 42:93–115. doi:10.1016/j.neubiorev.2014.
02.001
31. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, et al. Mul-
tiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s
disease diagnosis and prognosis. PLoS One (2011) 6(4):e18850. doi:10.1371/
journal.pone.0018850
32. Hanzel CE, Iulita MF, Eyjolfsdottir H, Hjorth E, Schultzberg M, Eriksdotter M,
et al. Analysis of matrix metallo-proteases and the plasminogen system in mild
cognitive impairment and Alzheimer’s disease cerebrospinal fluid. J Alzheimers
Dis (2014) 40(3):667–78. doi:10.3233/JAD-132282
33. Whitmer RA,GustafsonDR, Barrett-Connor E,HaanMN,Gunderson EP, Yaffe
K. Central obesity and increased risk of dementiamore than three decades later.
Neurology (2008) 71(14):1057–64. doi:10.1212/01.wnl.0000306313.89165.ef
34. Cheon MS, et al. Heart type fatty acid binding protein (H-FABP) is decreased
in brains of patients with Down syndrome and Alzheimer’s disease. J Neural
Transm Suppl (2003) 67:225–34.
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Delaby, Gabelle, Blum, Schraen-Maschke, Moulinier, Boulanghien,
Séverac, Buée, Rème and Lehmann. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordancewith
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org August 2015 | Volume 6 | Article 18111
